Objectives: Population optimal design is a tool to increase efficiency in drug development [1]. However, the population models used in drug development are becoming more and more advanced as the models incorporate additional variables like, for example, Time-To-Event (TTE), discrete type outcomes, etc. This increase in model complexity makes model-based optimal design more relevant but the […]
2010
Design of survival studies for red blood cells
Background: The lifespan of red blood cells (RBCs) is unknown. All current labelling methods contain significant flaws including loss of label from viable RBCs or reincorporation of the label into new RBCs after death of the originally labelled cells. Previously proposed models for the lifespan of RBCs either assume a fixed lifespan for all cells […]
Population pharmacokinetics of total and unbound melphalan in patients with multiple myeloma
Background: Melphalan, an alkylating agent, is an active chemotherapeutic agent in the treatment of multiple myeloma. High dose melphalan is used prior to autografting, but additional knowledge about the pharmacokinetics, combined with toxicity and efficacy data is needed to optimise the dose. Aims: To (1) investigate the pharmacokinetics of total and unbound plasma melphalan using a population approach […]
Developing a model for estimating lean body weight in children
Background: Body composition changes in relation to age and maturation. Mathematical models for estimating lean body weight (LBW) have been developed in adults. There are currently no models available to predict LBW in children as a function of age or maturation. Aim: To develop a semi-mechanistic model to estimate LBW in paediatric patients. Methods: (1)Using […]